CA2303598A1 - Dosage immunologique en tandem pour diagnostiquer le cancer - Google Patents

Dosage immunologique en tandem pour diagnostiquer le cancer Download PDF

Info

Publication number
CA2303598A1
CA2303598A1 CA 2303598 CA2303598A CA2303598A1 CA 2303598 A1 CA2303598 A1 CA 2303598A1 CA 2303598 CA2303598 CA 2303598 CA 2303598 A CA2303598 A CA 2303598A CA 2303598 A1 CA2303598 A1 CA 2303598A1
Authority
CA
Canada
Prior art keywords
cancer
breast cancer
cellular
ndp
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2303598
Other languages
English (en)
Other versions
CA2303598C (fr
Inventor
Gabriel Pulido-Cejudo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canbreal Therodiagnostics Canada Holding Corp
Canada Minister of Health
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002267481A external-priority patent/CA2267481A1/fr
Application filed by Individual filed Critical Individual
Priority to CA 2303598 priority Critical patent/CA2303598C/fr
Publication of CA2303598A1 publication Critical patent/CA2303598A1/fr
Application granted granted Critical
Publication of CA2303598C publication Critical patent/CA2303598C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA 2303598 1999-03-30 2000-03-30 Dosage immunologique en tandem pour diagnostiquer le cancer Expired - Fee Related CA2303598C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA 2303598 CA2303598C (fr) 1999-03-30 2000-03-30 Dosage immunologique en tandem pour diagnostiquer le cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2,267,481 1999-03-30
CA002267481A CA2267481A1 (fr) 1999-03-30 1999-03-30 Interdependance critique : du role de l'oestrogene dans le cancer du sein a la sensibilite des femmes a l'infection par le vih
CA 2303598 CA2303598C (fr) 1999-03-30 2000-03-30 Dosage immunologique en tandem pour diagnostiquer le cancer

Publications (2)

Publication Number Publication Date
CA2303598A1 true CA2303598A1 (fr) 2000-09-11
CA2303598C CA2303598C (fr) 2002-07-23

Family

ID=25680866

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2303598 Expired - Fee Related CA2303598C (fr) 1999-03-30 2000-03-30 Dosage immunologique en tandem pour diagnostiquer le cancer

Country Status (1)

Country Link
CA (1) CA2303598C (fr)

Also Published As

Publication number Publication date
CA2303598C (fr) 2002-07-23

Similar Documents

Publication Publication Date Title
BR0009484A (pt) Imunoensaio em série para câncer
Sokoloff et al. A dual‐monoclonal sandwich assay for prostate‐specific membrane antigen: Levels in tissues, seminal fluid and urine
Mikolajczyk et al. Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer
De Potter et al. The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues
AU2002211697B2 (en) Non-invasive enzyme screen for tissue remodelling-associated conditions
Goldschneider et al. Demonstration of terminal deoxynucleotidyl transferase in thymocytes by immunofluorescence.
Chenard et al. High levels of stromelysin‐3 correlate with poor prognosis in patients with breast carcinoma
AU720802B2 (en) Detection of cancer by assaying for cancer-specific antigens having linked oligosaccharides which are at least triantennary
WO2004065547A3 (fr) Antigene associe au cancer du pancreas, anticorps correspondant et methodes de diagnostic et de traitement
JP2006311860A (ja) 組織のリモデリングに関連した状態のための非観血的酵素スクリーン
Goldberg Proteases in the evaluation of pancreatic function and pancreatic disease
CN109813893A (zh) Cea检测试纸条及其制备方法、cea检测装置
Jain et al. Small integrin-binding proteins as serum markers for prostate cancer detection
US20030215900A1 (en) Non-invasive enzyme screen for cancer
Alanen et al. Immunohistochemical labelling for prostate–specific antigen in breast carcinomas
CA2303598A1 (fr) Dosage immunologique en tandem pour diagnostiquer le cancer
Corey et al. Characterization of 10 new monoclonal antibodies against prostate‐specific antigen by analysis of affinity, specificity and function in sandwich assays
CA2303505A1 (fr) Anticorps monoclonal anti-leucine aminopeptidase stimulee par l'oestrogene
Griffiths et al. The laboratory diagnosis of prostatic adenocarcinoma
Ban et al. Immunologic markers and the diagnosis of prostatic cancer
Bogdanowicz et al. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia
US8481273B2 (en) Perlecan fragments as biomarkers of bone stromal lysis
Ylätupa et al. Enzyme immunoassay for quantification of tenascin in biologic samples
Barbauche et al. Prognostic significance of autoantibodies to laminin in the sera of breast cancer patients: a preliminary report
WO2001065262A3 (fr) Reactifs et methodes de detection des pathologies mammaires

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed